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Abstract: Formulating common standards for the culture and quality control of umbilical cord
mesenchymal stromal cells (MSCs) is crucial for the standardization of clinical neurorestorative
therapy. But to date, there have been no standardized guidelines for the culture and quality control
of MSCs in neurorestorative clinical application. Based on a relatively comprehensive review of
published clinical studies as well as the existing methods of MSC culture and quality control,
the Chinese Association of Neurorestoratology has developed standards for the culture and
quality control of umbilical cord MSCs which possess the potential in neurorestorative clinical
application. These guidelines include standardized training and management procedures for
laboratory operators; standardized use and management of materials and equipment; standardized collection, culture and proliferation of umbilical cord MSCs; standardized management
for cell preservation, transport and related safeguard measures; as well as standardization of a
clean environment, routine maintenance and related tests and examinations and so on. These
guidelines represent the minimum required standards for the culture and quality control of
umbilical cord MSCs for potential use in current neurorestorative clinical therapy, and will be
further optimized according to the progress of preclinical and clinical studies.
Keywords: standardization, cell culture, quality control, mesenchymal stromal cells, clinical
treatment, neurorestoratology, translational medicine

Introduction
Mesenchymal stromal cells (MSCs), originating in the early development of the mesoderm, are fibroblastic-like cells, which can be derived from autologous or allogeneic
bone marrow, umbilical cord, adipose and other tissues in adults. Under distinctive
induction conditions, the stem cells among MSCs have the capacity to differentiate
into various types of tissues including bone, cartilage, fat and neurons. In 2006, the
International Society for Cellular Therapy (ISCT) established the minimal identification requirements to define human MSC. These include: 1) plastic-adherent when
maintained in standard culture conditions; 2) the positive expression of CD105, CD73
and CD90 and lack of expression of CD45, CD34, CD14 or CD11b, CD79a or CD19
and HLA-DR surface molecules; and 3) the ability of the cells to differentiate into
osteoblasts, adipocytes and chondroblasts in vitro.1–3 The ISCT released a document
again and highlighted the minimal identification criteria for MSCs in 2016.4 However,
many experts still mistake these criteria as the identification criteria of mesenchymal
stem cells. The ISCT suggests that all fibroblast-like plastic-adherent cells, regardless of the tissue from which they are isolated, should be termed multipotent MSCs.
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Investigators must clearly define the cell name used in their
reports.1 We have proposed the following guidelines in order
to bring clarification to the cultivation processes for MSCs
and avoid mistaking these for mesenchymal stem cells.
MSCs are derived from a wide range of sources.5–11 The
advantage of MSCs derived from umbilical cord is that the collection process is relatively simple and noninvasive; furthermore, the placental barrier protects the umbilical cord from
contamination by viruses and bacteria.12,13 A large number of
preclinical and clinical repair studies have been performed
on various systemic diseases, including neurologic disorders
and damage.14–24 But to date, there have been no standardized
guidelines for the culture and quality control of MSCs in the
neurorestorative clinical application. In order to ensure the
safety and effectiveness of clinical application of this type of
cells, it is important to standardize the cell culture and quality control processes. Based on a comprehensive review of
the published clinical studies as well as the existing methods
of MSC culture and quality control, the Chinese Association of Neurorestoratology has developed the following set
of standards for the culture and quality control of umbilical
cord MSCs in neurorestorative clinical application. These
guidelines include standardized training and management
procedures for laboratory operators; standardized use and
management of materials and equipment; standardized collection, culture and proliferation of umbilical cord MSCs;
standardized management for cell preservation, transport
and related safeguard measures; as well as standardization of
a clean environment, routine maintenance, related tests and
examinations and so on. The purpose of these standards is to
maximize the therapeutic efficacy, minimize the possible side
effects and promote the worldwide replicability of utilizing
umbilical cord MSCs for neurorestorative clinical application.

Standardized training and
management for operators
There should be at least one senior scientist/manager who is
in charge of overseeing the cell culture laboratory. The laboratory personnel should have an education background in cell
biology and receive systematic and professional training in
cell culture techniques and quality control management for
umbilical cord MSCs.
Basic standardized training schemes include knowledge
learning, skill development and familiarity with applicable
rules and regulations. Training methods include centralized
teaching, teacher demonstration, workshops, small seminars
or symposiums and so on. Training objectives include mastering professional knowledge, cell culture techniques and
12
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quality control processes for umbilical cord MSCs. A standardized management system includes filling and organizing
original work records and data, complying with the laboratory
maintenance standard operating procedures and current Good
Manufacturing Practices and completing operating records.

Standardized use and management
of materials and equipment
Cell culture laboratories must be managed by a designated
person who is responsible for the equipment maintenance,
regular calibration and personnel training. The designee
should maintain a normal operational status of clean rooms
and also establish and manage the equipment quality certification file records.
1. CO2 incubator: The temperature should be kept at a consistent 37°C and the concentration of CO2 at 5%.
2. Centrifuge: Be sure to balance the centrifugal object
before the centrifuge works.
3. Water bath box: Distilled water should be changed and
disinfected at least once a month.
4. Inverted microscope: The lens should be cleaned after
using an oil mirror. The power should be turned off and
the microscope should be covered after each use.
5. Super-clean bench or biologic safety cabinets: Operation
guidance for procedures should be strictly followed.
After finishing each program or procedure, the designated
person should determine whether all instruments are working
appropriately. The power should be turned off for equipment not
in use. Using records for equipment should be updated timely.

Umbilical cord MSC culture process
Donor selection
Female donors should have no history of infectious diseases
such as HIV, hepatitis B, hepatitis C or syphilis. Umbilical cord
should be derived from the fetal umbilical cord of normal,
cesarean birth or induced abortion without brain abnormalities. The cell procurement team should carry out the informed
consent process with potential donors and their families. After
understanding and consenting to the donation, the female donor
should sign the informed consent form. The process must be
approved by the relevant hospital ethics committees. Samples of
the umbilical cord should be kept in a sterile bag, then placed in
the freezer and delivered to the laboratory as soon as possible.

Culture medium
The culture medium of MSCs should consist of basal medium
and serum substitute. The basal medium components include
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combination of DMEM and F12 with 1:1 ratio (DF12). The
other components of the culture medium include glutamine,
fetal bovine serum and serum replacement. All materials
must meet the quality standards of sterile, nonpathogenic
microorganisms and endotoxins.

MSC cryopreservation and recovery
procedures

Umbilical cord MSC preparation
procedures
1. The sample tissue of umbilical cord should be put into
saline containing antibiotics. After being transferred to
the clean bench, the sample tissue should be placed on a
sterile culture dish. A stripping forceps is used to strip off
the outer membrane and blood vessels from the surface
of the umbilical cord carefully with naked eye, and the
integrity of the matrix layer should be maintained.
2. The tissue should be cut into granular tissue with sterile
scissors. The broken down pieces of tissue should be
taken into a 50 mL sterile centrifuge tube and centrifuged
under 1000 rpm for 5 minutes. The supernatant should be
discarded; saline containing antibiotics should be added,
the precipitated tissue blocks thoroughly mixed to make
them loose, and then they should be centrifuged under
1000 rpm for 5 minutes.
3. Tissue blocks are suspended with DF12 containing 15%
fetal bovine serum, fully mixed and then centrifuged
under 1000 rpm for 5 minutes. The tissue blocks are
precipitated evenly, grown on culture plastic flasks with
poly-lysine–coated surface and then placed in 5% CO2
incubator. After the tissue has completely adhered on the
flasks, the DF12 medium containing 15% fetal bovine
serum is added.
4. After culturing for about 14 days, on finding cell
adhesion, spindle cells or polygonal cells around the
tissue blocks under inverted microscope, suck out and
discarded all tissue blocks, then add DF12 containing
15% fetal bovine serum in the original flask, and continue
to culture cells in the 5% CO2 incubator.
5. In the next 1 week, cells grow rapidly and become relatively uniform in the shape of a long spindle with swirling
growth. When the cells cover 80% of the bottom of flask,
they should be digested with 0.25% trypsin-EDTA. The
cultured cells in one flask should be divided and taken
in two flasks in serum-free medium (with serum replacement) for passage. When the MSCs are passaged to the
fifth generation, they can be used for clinical application
or cryopreservation. In this step, antibiotic residues of the
cells need to be detected.
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Once the cells are vigorously growing and have covered the
culture flask (generally when they have fully filled the flasks)
at the fifth passage, they may be cryopreserved if they are
not to be used immediately for clinical application. Suck out
the medium from the flasks and add 2 mL of DF12 to each
flask to wash the cells. Add 2 mL of trypsin-EDTA to each
flask. After 2 minutes, add 2 mL of termination solution
to stop digestion. Fully blow and wash out the cells with a
thick elbow suction tube from one side to the other in order
to avoid creating foam. After centrifugation under 1000 rpm
for 5 minutes, the cells should be collected and then added
to the cell cryopreservation solution according to the amount
of MSCs. The cells are lightly blown with a thick elbow tube
to make them distribute evenly and then moved into the
cryopreservation tube. The number of the cells is marked and
the identification number of the sample recorded in order to
maintain good storage records.

Cryopreservation process
Cells should be processed at 4°C for 45 minutes, −20°C for
1 hour and then −80°C overnight. Finally, the processed cells
are transferred into a liquid nitrogen tank.
To resuscitate the sample for use in clinical application,
remove the frozen tube from the liquid nitrogen tank and
quickly immerse it into a hot 38.5°C water bath with continuous shaking to induce thawing as soon as possible. Use sterile
gauze to dry the surface of any excess water and use a straw
to suck out the cell suspension to a sterile 15 mL centrifuge
tube. Then add 10 mL of DF12 culture medium, blow the
cell suspension, and centrifuge for 5 minutes (1000 rpm)
and discard the supernatant. Then rinse the cells with DF12
medium for three times, and then put them into a culture flask
with DF12 medium without serum.

MSC quality control standards
Detecting exogenous factors in cell
products
Follow the current version of “China Pharmacopoeia” related
to biologic products, in order to detect any exogenous bacteria, fungi, mycoplasma and endotoxins.

Cell activity
Using trypan blue staining, cell activity should reach more
than 95%.
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Cellular immunophenotype
1. Morphologic identification: The morphologic characteristics of MSCs should be fibroblastic-like, spindle-shaped
and with a swirling growth under an inverted microscope.
2. Phenotype detection: Over 95% of the cells exhibited
positive surface antigenicity for CD73, CD90 and CD105,
and >99% of the cells were negative for CD34, CD45 and
HLA-DR, as measured by flow cytometry.2,25

Tumorigenicity
There have been no tumor formation reports after the transplantation of umbilical cord MSCs.

Cell quality control and management
Cell products must be double reviewed before using them in
any clinical transplant treatment. Laboratory personnel are
responsible for performing the double quality review and
testing, and should sign a standardized form indicating that
all checks have been satisfactorily carried out.26

Clinical cell dosage
The appropriate cell dosage should follow the Chinese clinical cell therapy guidelines for neurorestoration.27,28

Temperature and time control for clinical
cell transportation
Cell products should be kept at 4°C in a biosafety transport
box and be used within 2 hours after preparation.28

Management of clinical application
cell bank
Files of clinical therapeutic application and MSC cell bank
management system should be established according to
cell sources, the number of culture passage, location in the
liquid nitrogen tank, the date of cryopreservation and other
relevant details.

Summary
Formulating common standards for the culture and quality
control of umbilical cord MSCs is crucial for the standardization of clinical neurorestorative therapy. Our objective in
publishing this set of standards is to promote the worldwide
safety, effectiveness and replicability of utilizing umbilical
cord MSCs for neurorestorative clinical application. These
guidelines represent the minimum required standards for the
culture and quality control of umbilical cord MSCs for use
in current neurorestorative clinical therapy. These guidelines
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will be further optimized and improved according to the
progress of preclinical and clinical studies.
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